Moderna vs its peers
The 10 largest Biotechnology companies by market value, prices of Nov 20, 2026
Moderna is the 5th largest of the 10 biggest Biotechnology companies on OQRO by market value, at $78.9B. Its revenue of $1.94B in fiscal 2025 ranks 10th of 10. It runs at an operating loss of 158% of revenue, against a group median margin of 29%. Revenue fell 40% on the year before, against a median of +8.0%.
Side by side
| Company | Market value | Revenue | Growth y/y | 5-yr growth / yr | Gross margin | Operating margin | Net margin | Free cash flow margin | R&D / revenue | Price / earnings | Price / sales | FCF yield | Stock, 12 months |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AmgenAMGN · FY2025 | $236B | $36.8B | +10.0% | +7.6% | 67.2% | 24.7% | 21.0% | 22.0% | 19.8% | 30.6x | 6.4x | 3.4% | +29.6% |
| Gilead SciencesGILD · FY2025 | $206B | $29.4B | +2.4% | +3.6% | 78.8% | 34.0% | 28.9% | 32.1% | 19.7% | 24.3x | 7.0x | 4.6% |
Each company’s latest fiscal year (FY), so the years can end a few months apart. Price ratios divide today’s market value by that year’s figure; price / earnings is left out on a loss. “—” means the company did not tag that line in its annual report.
Operating margin
- UTHR47%
- EXEL38%
- VRTX35%
- GILD34%
- INCY29%
- REGN25%
- AMGN25%
- NBIX22%
- MRNA−158%
Compare Moderna head to head
Where Moderna’s revenue comes from and where it goes: Moderna revenue breakdown. Twenty years of results: Moderna financial history.
Common questions
Who are Moderna's competitors?
The largest companies in its industry (Biotechnology) by market value: Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Exelixis (EXEL) and Neurocrine Biosciences (NBIX). They share Moderna's industry listing; not every one competes with it on every product.
Is Moderna bigger than Amgen?
No, by market value: Moderna is worth $78.9B and Amgen $236B. By revenue, Moderna brought in $1.94B in fiscal 2025 and Amgen $36.8B in fiscal 2025.
How does Moderna's valuation compare with its peers?
Moderna trades at 40.6x its annual revenue. The median of the other 9 companies is 6.6x revenue and 24.3x earnings. A higher ratio means investors pay more for each dollar the company makes today, usually because they expect it to grow faster.
Where these figures come from
The group is the companies OQRO lists in the same industry as Moderna (Biotechnology), the largest 9 by market value, plus Moderna. Companies whose latest annual report is more than a year and a half old, or that report in a currency other than the dollar, are left out.
Revenue, operating income, net income, gross profit, research and development and free cash flow (cash from operations minus capital expenditure) are each company’s own full-year lines from its latest 10-K, as tagged in XBRL (SEC companyfacts). Market value is the last close times the shares outstanding on the latest filing. Price / earnings is market value over net income; price / sales is market value over revenue; free cash flow yield is free cash flow over market value. Five-year growth is the yearly rate that takes revenue from five fiscal years before to the latest. This page describes the past and is not investment advice. No language model wrote it.









